Moderna (BSP:M1RN34) Days Payable : 49.99 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Days Payable?

Moderna's average Accounts Payable for the three months ended in Dec. 2023 was R$2,494 Mil. Moderna's Cost of Goods Sold for the three months ended in Dec. 2023 was R$4,552 Mil. Hence, Moderna's Days Payable for the three months ended in Dec. 2023 was 49.99.

The historical rank and industry rank for Moderna's Days Payable or its related term are showing as below:

BSP:M1RN34' s Days Payable Range Over the Past 10 Years
Min: 22.32 Med: 32.88 Max: 572.37
Current: 34.22

During the past 8 years, Moderna's highest Days Payable was 572.37. The lowest was 22.32. And the median was 32.88.

BSP:M1RN34's Days Payable is ranked worse than
80.81% of 714 companies
in the Biotechnology industry
Industry Median: 148.12 vs BSP:M1RN34: 34.22

Moderna's Days Payable increased from Dec. 2022 (19.43) to Dec. 2023 (49.99). It may suggest that Moderna delayed paying its suppliers.

Moderna Days Payable Historical Data

The historical data trend for Moderna's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Days Payable Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

539.66

22.20

27.38

40.50

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															19.43	50.66	45.40	16.26	49.99

Competitive Comparison of Moderna's Days Payable

For the Biotechnology subindustry, Moderna's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Days Payable distribution charts can be found below:

* The bar in red indicates where Moderna's Days Payable falls into.

Moderna Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Moderna's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2554.51	+	2547.896)	/	2 )	/	22994.761	*	365
=	2551.203					/	22994.761	*	365
=	40.50

Moderna's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (2439.718	+	2547.896)	/	2 )	/	4551.914	*	365 / 4
=	2493.807					/	4551.914	*	365 / 4
=	49.99

Moderna Days Payable Related Terms

Thank you for viewing the detailed overview of Moderna's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (BSP:M1RN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (BSP:M1RN34) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna (BSP:M1RN34) Headlines

No Headlines